NHS Waiting List Data Shows Recovery Remains Uneven

NHS Waiting List Rises Again: What the July 2026 Figures Mean for Patients

The NHS waiting list for planned hospital treatment in England increased again in July 2026, underlining how uneven the recovery in elective care remains.

NHS England recorded around 7.33 million referral-to-treatment pathways waiting to start treatment at the end of July, up by almost 56,000 from 7.27 million in June.

Those pathways related to approximately 6.21 million individual patients.

That distinction matters. The headline waiting-list figure counts treatment pathways rather than unique people, so one patient can potentially appear on more than one pathway if they are waiting for different episodes of care.

The July figures also show why the national total should never be used on its own to predict an individual's experience.

Some specialties, hospitals and parts of England are performing considerably better than others, while the stage of the patient's pathway can make an enormous difference to how long treatment ultimately takes.

For people thinking about private medical insurance because of NHS waiting times, that makes the question more complicated than simply asking whether the national list is rising or falling.

What do the latest NHS waiting-list figures show?

At the end of July, around 7.33 million treatment pathways were waiting to begin consultant-led elective treatment in England.

That was an increase of 55,961 compared with June and represented the highest total since October 2025.

Around 65.4% of pathways were within 18 weeks, slightly below the 65.8% recorded in June.

Longer waits also increased.

An estimated 111,379 pathways had been waiting for more than 52 weeks, compared with 105,711 the previous month.

There were also 9,095 waits exceeding 65 weeks and 1,494 exceeding 78 weeks.

These figures show that the NHS has made progress from the very highest waiting-list levels seen following the pandemic, but recovery is not moving in a straight line.

Our Elective Treatment Access tracker follows these changes over time rather than looking at a single month's headline figure.

What does referral-to-treatment actually measure?

Referral-to-treatment, usually shortened to RTT, measures consultant-led elective care.

Broadly, the clock begins when a patient is referred for consultant-led treatment and continues until treatment starts or another event legitimately ends the pathway.

That can include somebody waiting for their first specialist appointment, somebody undergoing investigations or somebody who has already been diagnosed and is waiting for a procedure.

This means two people counted within the same national waiting list can be at very different stages of care.

One may be waiting for an initial orthopaedic consultation.

Another may already have seen a consultant, undergone an MRI and been told they need surgery.

Their remaining waits may therefore look completely different even though both appear within the same national RTT statistics.

Why the national waiting-list total only tells part of the story

The 7.33 million figure is useful because it shows the scale of pressure across England.

It does not tell an individual patient how long they will wait.

Waiting times vary according to speciality, hospital trust, local capacity and clinical priority.

The availability of orthopaedic care may look very different from ophthalmology, ENT or dermatology.

There can also be substantial variation between neighbouring hospitals.

A national figure can therefore improve while a particular specialty deteriorates, or rise while access improves in another part of the system.

This is one reason our Treatment Access Index looks beyond a single waiting-list number and brings together elective treatment, diagnostics, time-critical pathways, wider system pressure and patient access measures.

The aim is to provide context rather than suggest that one national statistic represents every patient's experience.

Diagnostics can be just as important as the treatment wait

The treatment waiting list also does not tell the whole story about how quickly somebody reaches a diagnosis.

A typical healthcare journey may involve a GP consultation, specialist referral, diagnostic investigation, another consultant appointment and then treatment.

Delays can occur at any stage.

For someone experiencing unexplained symptoms, waiting for an MRI, CT scan, endoscopy or another diagnostic test may be just as important as the eventual wait for treatment.

Our Diagnostic Access tracker follows NHS diagnostic pressure separately for that reason.

NHS England reported record diagnostic activity during June and July 2026, with more than 5.3 million tests and checks carried out across the two months.

Higher activity is encouraging, but demand matters too.

Performing more tests does not automatically mean every patient's wait becomes shorter if referrals are also increasing.

A rising waiting list does not necessarily mean the NHS is treating fewer people

This is another important distinction.

Waiting lists are affected by both the number of people entering the system and the number completing treatment.

A list can increase even while hospitals are treating more patients if new referrals are growing faster than completed pathways.

NHS England has emphasised that demand remained exceptionally high during the summer of 2026.

The July increase should therefore not simply be interpreted as evidence that hospitals suddenly became less productive.

It reflects the balance between incoming demand and the NHS's ability to diagnose and treat that demand.

That is why the direction of one month's headline list needs context.

What do the figures mean for somebody considering PMI?

Waiting times are one reason people consider private medical insurance.

PMI can provide an alternative route to eligible private consultations, diagnostics and planned treatment for certain medical conditions.

But it is important to be precise about what that means.

Private medical insurance is not a mechanism for simply transferring an existing NHS waiting-list problem into private care.

Policies are generally designed to cover eligible new acute conditions arising after cover begins, subject to underwriting, exclusions and the policy's benefits.

Our guide to what private medical insurance covers and what it doesn't explains the distinction.

The relevance of PMI is therefore mainly about giving somebody another potential treatment route for eligible future medical needs.

Existing symptoms and referrals can affect cover

This becomes particularly important if someone begins looking at PMI because they are already waiting for NHS treatment.

If symptoms started before the insurance began, or the person has already seen a GP, been investigated or been referred for treatment, the condition may be treated as pre-existing.

Buying insurance after an NHS referral has started does not normally mean the insurer will automatically fund that existing problem privately.

Our guide to private medical insurance and pre-existing conditions explains how underwriting can affect existing symptoms and medical history.

Anyone considering cover because of a current NHS wait should understand this before assuming the policy provides an immediate alternative.

Faster access depends on the whole private pathway

Even where a condition is covered, the first appointment is only part of the story.

A patient might receive a private consultant appointment relatively quickly but still need further investigations before a treatment decision can be made.

For example, somebody with persistent knee pain may need an orthopaedic consultation followed by an MRI before the consultant can determine whether surgery is appropriate.

The availability of the consultant, scan and eventual procedure all matter.

Our guide to whether PMI covers MRI and CT scans explains why diagnostic benefits and outpatient limits can be important when comparing policies.

This is why simply advertising a fast first appointment can give an incomplete picture of private healthcare access.

The useful question is:

How quickly can I move through the entire pathway from consultation to diagnosis and, if required, treatment?

Policy design can affect access too

Not every private medical insurance policy gives access to the same hospitals, consultants or level of outpatient treatment.

Hospital lists can restrict where treatment is available.

Guided consultant arrangements can influence which specialist somebody can see.

Outpatient limits can affect how much consultation or diagnostic treatment is covered.

An excess may need to be paid when a claim is made.

Pre-authorisation may also be required before appointments, scans or procedures are booked.

These features can reduce the premium, but they can also affect the practical experience of making a claim.

That is why comparing PMI solely on monthly price can be misleading.

A cheaper policy may be perfectly suitable, but the customer needs to understand what has been restricted to produce that price.

PMI does not replace emergency NHS services

Waiting-list discussions mainly concern planned treatment.

Emergency medicine is different.

Private medical insurance does not normally replace A&E departments, ambulance services or emergency stabilisation.

Someone experiencing a suspected heart attack, stroke, serious injury, severe breathing difficulty or another emergency should use the appropriate NHS emergency service.

Our guide to emergency treatment and private medical insurance explains where private insurance may become relevant later if eligible planned follow-up treatment is required.

PMI and the NHS therefore frequently work alongside one another rather than functioning as competing complete healthcare systems.

Local waiting times matter more than the national average

For somebody currently using the NHS, the most useful information may be much closer to home than the national waiting-list total.

It can be useful to understand the position for the relevant hospital and speciality.

A national increase from 7.27 million to 7.33 million does not tell an individual patient whether their local orthopaedic service has improved.

Likewise, a national fall would not guarantee that their particular pathway had become faster.

NHS England now publishes provider-level information allowing waiting times to be compared across hospital trusts.

Patients should also speak to the clinicians involved in their care rather than attempting to calculate their own likely treatment date from national statistics.

Data can also be revised

Monthly NHS statistics are an important source of information, but they should not be treated as perfectly fixed numbers.

NHS England periodically revises referral-to-treatment data as providers validate and update their returns.

The organisation revised earlier 2025 and 2026 figures in July, for example.

Some national time series may also contain estimates where complete data is unavailable from individual trusts.

That does not make the statistics unreliable.

It means small month-to-month changes need to be interpreted sensibly rather than treated as proof of a dramatic change in NHS performance.

The longer-term direction is usually more informative.

Is the NHS waiting list improving?

The fairest answer is that the picture is mixed.

The NHS has reduced the waiting list from its post-pandemic peak and is carrying out very large numbers of treatments and diagnostic procedures.

But July saw the headline list rise again.

The number of year-long waits also increased and only around 65% of pathways were within 18 weeks.

So the system is neither in uninterrupted decline nor experiencing a straightforward recovery.

Progress varies by month, speciality and location.

That unevenness is exactly why we track NHS access across several measures through the Treatment Access Index, rather than treating one monthly number as the definitive verdict on the health service.

What should somebody considering PMI take from the figures?

The July waiting-list release provides useful evidence of continued pressure on elective care.

It does not prove that every NHS patient is waiting longer.

It does not mean every private patient will be treated immediately.

And it does not mean somebody currently waiting for NHS treatment can buy insurance today and automatically have that existing condition covered privately.

The more useful conclusion is that access remains uneven.

For people who want another potential route to diagnosis and planned treatment for future eligible medical conditions, PMI may be worth considering.

But the policy needs to be judged on what it actually covers.

Hospital access, outpatient benefits, diagnostics, consultant choice, underwriting, exclusions and excess can all affect how useful it becomes when somebody needs to claim.

For a wider introduction, read what private medical insurance covers and what it doesn't.

You can also explore the latest NHS access figures through our Treatment Access Index, Elective Treatment Access tracker and Diagnostic Access tracker.

If you want to compare private medical insurance and understand how different policy options affect access, you can request a PMI quote.

Sources

NHS England — Consultant-led Referral to Treatment Waiting Times

NHS England — Consultant-led Referral to Treatment Waiting Times, July 2026, published 10 September 2026.

This article is for general information only and does not constitute medical or insurance advice. NHS waiting times vary by location, speciality and individual clinical circumstances. Private medical insurance cover depends on underwriting, exclusions, benefits and the terms of the individual policy.